EU regulator backs Novo's hemophilia A preventive therapy and recommends seven additional drugs

The European Medicines Agency's human medicines committee issued a positive opinion on Novo's preventive treatment for hemophilia A, indicating it meets the agency's standards for further development.

The same committee also recommended approval for seven other new medicines, suggesting they have demonstrated sufficient efficacy and safety to move toward market authorization.

In addition, the CHMP proposed 11 label expansions for existing products, highlighting broader therapeutic uses that could affect market access and investor interest.